Unit | Clinical Immunology

Our group focuses on systems-immunology-based approaches within the framework of Phase I to III clinical trials. We aim to identify surrogates of protection as well as host factors elicited by subunit and whole parasite vaccines against tuberculosis (TB) and malaria. Clinical trials are performed with our partners of the Ifakara Health Institute in Bagamoyo. Further, the unit develops novel diagnostic tools for paediatric clinical TB in high endemic countries.


Co-morbidity studies analyse the impact of non-communicable diseases on immune responses against infectious diseases, particularly TB. Unit researchers also work to understand the consequences of helminth co-infections on malaria, TB and HIV pathogenesis and immunity.

Vogel G et al. Functional characterization and phenotypic monitoring of human hematopoietic stem cell expansion and differentiation of monocytes and macrophages by whole-cell mass spectrometry. Stem Cell Res. 2018;26:47-54. DOI: 10.1016/j.scr.2017.11.013

Olotu A et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and Immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in health. Am J Trop Med Hyg. 2017(in press). DOI: 10.4269/ajtmh.17-0449

Kassim A, Pflüger V, Premji Z, Daubenberger C, Revathi G. Comparison of biomarker based Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) and conventional methods in the identification of clinically relevant bacteria and yeast. BMC Microbiol. 2017;17:128. DOI: 10.1186/s12866-017-1037-z

Mpina M et al. Controlled human malaria infection leads to long-lasting changes in innate and innate-like lymphocyte populations. J Immunol. 2017;199:107-118. DOI: 10.4049/jimmunol.1601989

Moncunill G et al. Distinct helper T cell type 1 and 2 responses associated with malaria protection and risk in RTS,S/AS01E vaccinees. Clin Infect Dis. 2017;65(5):746-755. DOI: 10.1093/cid/cix429